Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Aprepitant · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Aprepitant | DRUG | - |
| Ondansetron | DRUG | - |
| GW679769 | DRUG | - |
| Dexamethasone | DRUG | - |
Inclusion criteria: * Willing to provide a written informed consent prior to receiving any study-specific procedures or assessments. * Diagnosed with a solid malignant tumour and has not previously received chemotherapy. * Scheduled to receive chemotherapy conducive to regimens outlined in the stud...
Aprepitant is used for the prevention of nausea and vomiting in cancer patients receiving highly emetogenic cisplatin-based chemotherapy. It is being studied in the oncology therapeutic area for chemotherapy-induced nausea and vomiting. The drug is a small molecule currently in Phase 2 clinical development.
Aprepitant is a small molecule that targets the neurokinin-1 receptor, which plays a role in the emetic response. By blocking this receptor, it helps prevent nausea and vomiting triggered by chemotherapy. This mechanism is being evaluated in a Phase 2 clinical trial for chemotherapy-induced nausea and vomiting.
Aprepitant is being developed by GSK plc, a biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical research to evaluate the drug's safety and efficacy for the prevention of nausea and vomiting in cancer patients receiving cisplatin-based chemotherapy.
Aprepitant is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The drug is being studied for its potential to prevent chemotherapy-induced nausea and vomiting in cancer patients, with one completed Phase 2 trial involving 492 participants.
Aprepitant has one completed clinical trial registered under NCT00169572, titled 'Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy.' This Phase 2 trial enrolled 492 participants across multiple countries, including Argentina, Austria, Belgium, Chile, Croatia, Czechia, Hong Kong, Hungary, Italy, Mexico, Netherlands, Pakistan, Peru, Philippines, Poland, Romania, Singapore, Slovakia, and Taiwan.
Aprepitant is the active ingredient in the brand-name drug Emend, which is used for the prevention of chemotherapy-induced nausea and vomiting. The clinical trial data provided refers to Aprepitant as the investigational drug, and it is being developed by GSK plc under the ticker GSK.